IN OVO CARCINOGENICITY ASSAY (IOCA)

物质的致癌性测试目前通过在两年研究中利用啮齿动物进行的昂贵的生物测定来评估。本项目的目的是开发一种替代试验，用于禽类胚胎的致癌性筛选试验。卵内致癌性试验（IOCA），在受精的火鸡蛋中进行，它解决了动物试验的三个R（减少，改进和替代）。与啮齿动物生物测定法相比，IOCA具有许多优点，包括：1）它是一种快速测试，最多需要24天进行; 2）测试不需要使用任何哺乳动物; 3）测试是在蛋上进行的，蛋保存在孵化器中，比动物设施需要更少的空间和设备; 4）剂量小，减少了人类对潜在致癌物的暴露;和5）与传统的致癌性测试相比，分析成本大大降低。我们建议通过检测已知致癌物并将结果与两年啮齿动物生物测定的结果进行比较，证明IOCA作为替代致癌性测定的实用性。通过证明IOCA识别致癌物质的预测性和敏感性，我们将建立IOCA作为一种商业上可行的技术的可行性。拟议的商业应用：MB Research将为制药、生物技术、化妆品、化学和消费品行业提供IOCA。我们目前为客户进行标准啮齿动物生物测定和加速啮齿动物致癌研究，以及几项基于鸡蛋的研究。对我们客户的一项调查表明，需要一种替代测试，可以快速，廉价地筛查潜在的致癌物质。因此，我们在满足这一行业需求方面具有独特的优势，可以将这项技术提供给愿意接受的客户群，从而占据了测试市场的很大一部分。

Carcinogenicity testing of substances is currently assessed via costly bioassays utilizing rodents in two year studies. The objective of this project is to develop an alternative assay which is performed on avian embryos as a screening test for carcinogenicity. The in ovo carcinogenicity assay (IOCA), conducted in fertilized turkey eggs, which addresses the three R's (reduction, refinement and replacement) of animal testing. The IOCA has numerous advantages over the rodent bioassay, including: 1) it is a rapid test, requiring a maximum of 24 days to perform; 2) testing does not require use of any mammals; 3) testing is performed on eggs, which are kept in incubators, requiring less space and equipment than animal facilities; 4) dose amounts are small, which reduces exposure of humans to potential carcinogens; and 5) cost of analysis is greatly reduced when compared to traditional carcinogenicity testing. We propose to demonstrate the utility of the IOCA as an alternative carcinogenicity assay by testing known carcinogens and comparing the results to those from two year rodent bioassays. By demonstrating the predictivity and sensitivity of IOCA to identify carcinogenic substances, we will establish the feasibility of IOCA as a commercially viable technology. PROPOSED COMMERCIAL APPLICATIONS: MB Research will offer the IOCA to the pharmaceutical, biotech, cosmetic, chemical and consumer products industries. We currently perform standard rodent bioassays and accelerated rodent carcinogenesis studies, as well as several egg-based studies for our clients. A survey of our clients indicates a demand for an alternative test that allows for rapid, inexpensive screening of potential carcinogenic substances. Thus, we are uniquely positioned to fulfill this industry demand and can provide this technology to a receptive client base, capturing a significant portion of the testing market.